Buscar
Biodexa Pharmaceuticals PLC
BDRXAñadir a la lista de seguimiento
3.300USD
-0.100-2.94%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
2.46MCap. mercado
18.93P/E TTM
Más Datos de Biodexa Pharmaceuticals PLC Compañía
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Información de Biodexa Pharmaceuticals PLC
Símbolo de cotizaciónBDRX
Nombre de la empresaBiodexa Pharmaceuticals PLC
Fecha de salida a bolsaDec 08, 2014
Director ejecutivoStamp (Stephen A)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 08
Dirección1 Caspian Point
CiudadABINGDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCF10 4DQ
Teléfono4401235888300
Sitio Webhttps://www.biodexapharma.com/
Símbolo de cotizaciónBDRX
Fecha de salida a bolsaDec 08, 2014
Director ejecutivoStamp (Stephen A)
Ejecutivos de Biodexa Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Desglose de ingresos
Divisa: USDActualizado: jue., 2 de abr
Divisa: USDActualizado: jue., 2 de abr
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
Belgium
381.00K
100.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 4 de may
Actualizado: lun., 4 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sabby Management, LLC
5.88%
Armistice Capital LLC
0.62%
Brio Capital Management LLC
0.52%
GAMMA Investing LLC
0.43%
HRT Financial LP
0.33%
Otro
92.23%
Accionistas
Accionistas
Proporción
Sabby Management, LLC
5.88%
Armistice Capital LLC
0.62%
Brio Capital Management LLC
0.52%
GAMMA Investing LLC
0.43%
HRT Financial LP
0.33%
Otro
92.23%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
6.82%
Hedge Fund
0.63%
Investment Advisor
0.33%
Individual Investor
0.08%
Otro
92.14%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
26
66.51K
7.79%
+60.31K
2025Q4
25
26.99K
4.95%
--
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sabby Management, LLC
190.66K
5.88%
+190.66K
--
Dec 31, 2025
Armistice Capital LLC
100.00K
3.08%
+100.00K
--
Dec 31, 2025
Brio Capital Management LLC
16.77K
0.52%
+11.06K
+193.61%
Nov 14, 2024
GAMMA Investing LLC
1.78K
0.05%
+425.00
+31.43%
Dec 31, 2025
HRT Financial LP
10.58K
0.33%
+10.58K
--
Dec 31, 2025
District 2 Capital LP
403.00
0.01%
-449.00
-52.70%
Nov 11, 2024
SBI Securities Co., Ltd.
101.00
0%
-14.00
-12.17%
Dec 31, 2025
UBS Switzerland AG
183.00
0.01%
-6.74K
-97.36%
Dec 31, 2025
Hilton Head Capital Partners, LLC
30.00
0%
+30.00
--
Dec 31, 2025
Rhumbline Advisers Ltd. Partnership
24.00
0%
+19.00
+380.00%
Dec 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 18, 2026
Merger
5→1
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Mar 18, 2026
Merger
5→1
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Ver más
